Search
Search results
74 results found
Lab Members
A New Approach to the Development of Disease-Modifying Therapies for PD
Simon, David K. 2021. “A New Approach to the Development of Disease-Modifying Therapies for PD”. Movement Disorders.
Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology
Simon, David K., Caroline M. Tanner, and Patrik Brundin. 2020. “Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology”. Clinical Geriatric Medicine.
Transportation innovation to aid Parkinson disease trial recruitment
Frank, Samuel, Sarah Berk, Laura Hernandez, Penelope Hogarth, Holly A Shill, Bernadette Siddiqi, and David K Simon. 2019. “Transportation Innovation to Aid Parkinson Disease Trial Recruitment”. Contemporary Clinical Trials Communications.
The inverse association of cancer and Alzheimer's: A bioenergetic mechanism
Demetrius, LA, and DK Simon. 2013. “The Inverse Association of Cancer and Alzheimer’s: A Bioenergetic Mechanism”. Journal of the Royal Society Interface.
Somatic mitochondrial DNA mutations in early Parkinson's and incidental Lewy body disease
Lin, MT, I Cantuti-Castelvetri, K Zheng, KE Jackson, YB Tan, T Arzberger, AJ Lees, RA Betensky, MF Beal, and DK Simon. 2012. “Somatic Mitochondrial DNA Mutations in Early Parkinson’s and Incidental Lewy Body Disease”. Annals of Neurology.
Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease
Clark, Joanne, Sonika Reddy, Kangni Zheng, Rebecca A Betensky, and David K Simon. 2011. “Association of PGC-1alpha Polymorphisms With Age of Onset and Risk of Parkinson’s Disease”. BMC Med Genet.
Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation
Dai, Ying, Kangni Zheng, Joanne Clark, Russell H Swerdlow, Stefan M Pulst, James P Sutton, Leslie A Shinobu, and David K Simon. 2013. “Rapamycin Drives Selection Against a Pathogenic Heteroplasmic Mitochondrial DNA Mutation”. Hum Mol Genet.
Our Scientific Approach
Our lab focuses on unraveling the biochemistry and neuropathology underlying this complex neurodegenerative disorder. We take a systems-level approach to investigate the molecular mechanisms driving disease progression, particularly focusing on key protein pathways, including VPS35, USP30, LRRK2...